ConductScience.org, home

Comparison · NCT03795298-c4618e98

Oral Anticoagulant (Control) vs WATCHMAN FLX DEVICE: Primary Safety Endpoint: Non-procedural Bleeding

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Oral Anticoagulant (Control) vs WATCHMAN FLX DEVICE: Primary Safety Endpoint: Non-procedural Bleeding. Trial comparisons, record NCT03795298-c4618e98. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03795298-c4618e98

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1720.1470.2wilson
Risk in group 20.08090.0640.102wilson
Risk difference, group 1 minus group 20.09090.05870.123newcombe hybrid score
Risk ratio, group 1 over group 22.121.612.81log
Odds ratio, group 1 over group 22.361.723.22log
Number needed to treat, for one more participant with the outcome on Oral Anticoagulant (Control) than on WATCHMAN FLX DEVICE118.117from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Oral Anticoagulant (Control)Catheter ablation for atrial ablation followed by market-approved OAC for the duration of the trial137797OG000
Group 2WATCHMAN FLX DEVICECatheter ablation for atrial fibrillation followed by WATCHMAN FLX Device implant with market-approved OAC and aspirin until the 3-month visit followed by aspirin until at least the 12-month visit65803OG001

Outcome

Type
PRIMARY
Title
Primary Safety Endpoint: Non-procedural Bleeding
Description
Occurrence of non-procedural bleeding (ISTH major bleeding and clinically relevant non-major bleeding) events adjudicated by an Independent Clinical Event Committee
Time frame
Non-procedural events are those occurring after 3 days, calculated from implant or attempted implant date for Device patients and from date of randomization for Control patients
Population
The primary analysis for the primary safety endpoint was performed on an intent-to-treat basis, with all randomized subjects analyzed as part of their randomized group regardless of the actual treatment received

Source ClinicalTrials.gov

Trial

Title
Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation
NCT number
NCT03795298
Phases
NA
Conditions
Atrial Fibrillation
Interventions
WATCHMAN FLX Implant, Market-approved OAC
Lead sponsor
Boston Scientific Corporation
Results first posted
2025-09-18

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03795298-c4618e98